You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 2, 2024

Details for New Drug Application (NDA): 215151


✉ Email this page to a colleague

« Back to Dashboard


NDA 215151 describes VOQUEZNA, which is a drug marketed by Phathom and is included in three NDAs. It is available from one supplier. There are two patents protecting this drug. Additional details are available on the VOQUEZNA profile page.

The generic ingredient in VOQUEZNA is amoxicillin; clarithromycin; vonoprazan fumarate. There are forty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the amoxicillin; clarithromycin; vonoprazan fumarate profile page.
Summary for 215151
Tradename:VOQUEZNA
Applicant:Phathom
Ingredient:vonoprazan fumarate
Patents:2
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 215151
Generic Entry Date for 215151*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Suppliers and Packaging for NDA: 215151
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VOQUEZNA vonoprazan fumarate TABLET;ORAL 215151 NDA Phathom Pharmaceuticals Inc. 81520-100 81520-100-30 30 TABLET in 1 BOTTLE, PLASTIC (81520-100-30)
VOQUEZNA vonoprazan fumarate TABLET;ORAL 215151 NDA Phathom Pharmaceuticals Inc. 81520-200 81520-200-30 30 TABLET in 1 BOTTLE, PLASTIC (81520-200-30)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 10MG BASE
Approval Date:Nov 1, 2023TE:RLD:Yes
Regulatory Exclusivity Expiration:May 3, 2027
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Regulatory Exclusivity Expiration:Nov 1, 2026
Regulatory Exclusivity Use:NEW PRODUCT
Patent:⤷  Try a TrialPatent Expiration:Aug 11, 2028Product Flag?Substance Flag?YDelist Request?

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.